Genetic susceptibility and pulmonary fibrosis

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 5, 2014, Pages 429-435

  Mathai, Susan K ^a   Schwartz, David A ^a,b   Warg, Laura A ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

desmosome; idiopathic pulmonary fibrosis; MUC5B; pulmonary fibrosis; telomere

Indexed keywords

AGING; CELL ADHESION; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; HUMAN; LUNG FIBROSIS;

AGING; CELL ADHESION; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; PULMONARY FIBROSIS;

EID: 84906044121     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000074     Document Type: Review

References (69)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
2. King TE, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 164:1171-1181.
3. Baumgartner KB, Samet JM, Stidley CA, et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155:242-248.
4. Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Am J Epidemiol 2000; 152:307-315.
5. Hubbard R, Lewis S, Richards K, et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996; 347:284-289.
6. Hubbard R, Venn A, Smith C, et al. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis-a case-control study. Am J Respir Crit Care Med 1998; 157:743-747.
7. Bonanni PP, Frymoyer JW, Jacox RF. A family study of idiopathic pulmonary fibrosis: a possible dysproteinemic and genetically determined disease. Am J Med 1965; 39:411-421.
8. Javaheri S, Lederer DH, Pella JA, et al. Idiopathic pulmonary fibrosis in monozygotic twins: the importance of genetic predisposition. Chest 1980; 78:591-594.
9. Solliday NH, Williams JA, Gaensler EA, et al. Familial chronic interstitial pneumonia. Am Rev Respir Dis 1973; 108:193-204.
10. Bitterman PB, Rennard SI, Keogh BA, et al. Familial idiopathic pulmonary fibrosis: evidence of lung inflammation in unaffected family members. N Engl J Med 1986; 314:1343-1347.
11. Nogee LM, Dunbar AE, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344:573-579.
12. Fernandez BA, Fox G, Bhatia R, et al. A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features. Respir Res 2012; 13.
13. Maitra M, Cano CA, Garcia CK. Mutant surfactant A2 proteins associated with familial pulmonary fibrosis and lung cancer induce TGF-b1 secretion. Proc Natl Acad Sci 2012; 109:21064-21069.
14. Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat Res 2012; 730:52-58.
15. Gochuico BR, Huizing M, Golas GA, et al. Interstitial lung disease and pulmonary fibrosis in Hermansky-Pudlak syndrome type 2, an adaptor pro-tein-3 complex disease. Molec Med (Cambridge, Mass) 2012; 18:56-64.
16. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364:1503-1512.
17. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nature Genet 2013; 45:613-620.
18. Noth I, Zhang Y, Ma S-F, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013; 1:309-317.
19. Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter polymor-phism and interstitial lung abnormalities. N Engl J Med 2013; 368:2192-2200.
20. Peljto AL, Zhang YZ, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. J Am Med Assoc 2013; 309:2232-2239.
21. Garćia-Sancho C, Buend́ia-Roldán I, Fernández-Plata MR, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 2011; 105:1902-1907.
22. Ahn MH, Park BL, Lee SH, et al. A promoter SNP rs4073T < A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode. Respir Res 2011; 12:73.
23. Hutyrova B, Pantelidis P, Drabek J, et al. Interleukin-1 gene cluster polymorph isms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 165:148-151.
24. Whyte M, Hubbard R, Meliconi R, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 2000; 162:755-758.
25. Seibold MA, Smith RW, Urbanek C, et al. The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One 2013; 8:e58658.
26. Zhang Y, Noth I, Garcia JGN, Kaminski N. A variantin the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med 2011; 364:1576-1577.
27. Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68:436-441.
28. Borie R, Crestani B, Dieude P, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One 2013; 8:e70621.
29. Peljto AL, Steele MP, Fingerlin TE, et al. The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest 2012; 142:1584-1588.
30. Kamio K, Matsushita I, Hijikata M, et al. Promoter analysis and aberrant expression of the MUC5B gene in diffuse panbronchiolitis. Am J Respir Crit Care Med 2005; 171:949-957.
31. Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. Nature 2014; 505:412-416.
32. O'Dwyer DN, Armstrong ME, Trujillo G, et al. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013; 188:1442-1450.
33. Kukkonen MK, Vehmas T, Piirila P, Hirvonen A. Genes involved in innate immunity associated with asbestos-related fibrotic changes. Occup Environ Med 2014; 71:48-54.
34. Minagawa S, Araya J, Numata T, et al. Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-beta-induced senescence of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2011; 300:L391-L401.
35. Chilosi M, Poletti V, Murer B, et al. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of Delta N-p63. Lab Invest 2002; 82:1335-1345.
36. Chilosi M, Carloni A, Rossi A, Poletti V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl Res 2013; 162:156-173.
37. Korthagen NM, van Moorsel CHM, Barlo NP, et al. Association between variations in cell cycle genes and idiopathic pulmonary fibrosis. PLoS One 2012; 7:e30442.
38. Codd V, Nelson CP, Albrecht E, et al. Identification of seven loci affecting mean telomere length and their associationwith disease. Nature Genet 2013; 45:422-427.
39. Liu TJ, Ullenbruch M, Choi YY, et al. Telomerase and telomere length in pulmonary fibrosis. Am J Respir Crit Care Med 2013; 49:260-268.
40. Armanios MY, Chen JJL, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356:1317-1326.
41. Alder JK, Cogan JD, Brown AF, et al. Ancestral mutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis. PLoS Genet 2011; 7:e1001352.
42. Nunes H, Monnet I, Kannengiesser C, et al. Is telomeropathy the explanation for combined pulmonary fibrosis and emphysema syndrome? Report of a family with TERT mutation. Am J Respir Crit Care Med 2014; 189:753-754.
43. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178:729-737.
44. Alder JK, Chen JJL, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008; 105:13051-13056.
45. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104:7552-7557.
46. Mushiroda T, Wattanapokayakit S, Takahashi A, et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet 2008; 45:654-656.
47. Tsang AR, Wyatt HDM, Ting NSY, Beattie TL. hTERT mutations associated with idiopathic pulmonary fibrosis affect telomerase activity, telomere length, and cell growth by distinct mechanisms. Aging Cell 2012; 11:482-490.
48. Kropski JA, Lawson WE, Young LR, Blackwell TS. Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis. Dis Model Mech 2013; 6:9-17.
49. Kropski JA, Mitchell DB, Markin C, et al. A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest 2014. [Epub ahead of print]
50. Levy D, Neuhausen SL, Hunt SC, et al. Genome-wide association identifies OBFC1 as a locus involved in human leukocyte telomere biology. Proc Natl Acad Sci USA 2010; 107:9293-9298.
51. Maubaret CG, Salpea KD, Romanoski CE, et al. Association of TERC and OBFC1 haplotypeswith mean leukocyte telomere length and risk for coronary heart disease. PLoS One 2013; 8.
52. Lee JH, Cheng R, Honig LS, et al. Genome wide association and linkage analyses identified three loci-4q25, 17q23. 2, and 10q11. 21-associated with variation in leukocyte telomere length: the Long Life Family Study. Front Genet 2013; 4:310.
53. Rasmussen TB, Hansen J, Nissen PH, et al. Protein expression studies of desmoplakin mutations in cardiomyopathy patients reveal different molecular disease mechanisms. Clin Genet 2013; 84:20-30.
54. den Haan AD, Tan BY, Zikusoka MN, et al. Comprehensive desmosome mutation analysis in North Americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet 2009; 2:428-435.
55. Yu DMT, Wang XM, Ajami K, et al. DP8 and DP9 have extra-enzymatic roles in cell adhesion, migration and apoptosis. In: Lendeckel U, Reinhold D, Bank U, editors. Dipeptidyl aminopeptidases: basic science and clinical applications. New York: Springer; 2006. pp. 63-72.
56. Carloni A, Poletti V, Fermo L, et al. Heterogeneous distribution of mechanical stress in human lung: a mathematical approach to evaluate abnormal remodeling in IPF. J Theor Biol 2013; 332:136-140.
57. Yang IV. Epigenomics of idiopathic pulmonary fibrosis. Epigenomics 2012; 4:195-203.
58. Chilosi M, Poletti V, Zamo A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162:1495-1502.
59. Konigshoff M, Balsara N, Pfaff EM, et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 2008; 3.
60. Konigshoff M, Kramer M, Balsara N, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 2009; 119:772-787.
61. Chen YJ, Lee LY, Chao YK, et al. DSG3 facilitates cancer cell growth and invasion through the DSG3-plakoglobin-TCF/LEF-Myc/cyclin D1/MMP signaling pathway. PLoS One 2013; 8:e64088.
62. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172:1146-1152.
63. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc 2006; 3:293-298.
64. Taskar V, Coultas D. Exposures and idiopathic lung disease. Semin Respir Crit Care Med 2008; 29:670-679.
65. Rabinowits M, Souhami L, Gil RA, et al. Increased pulmonary toxicity with bleomycin and cisplatin chemotherapy combinations. Am J Clin Oncol 1990; 13:132-138.
66. Brusamolino E, Lunghi F, Orlandi E, et al. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Haematologica 2000; 85:1032-1039.
67. Abratt RP, Morgan GW, Silvestri G, Willcox P. Pulmonary complications of radiation therapy. Clin Chest Med 2004; 25:167-177.
68. Mehta V. Radiation pneumonitis and pulmonary fibrosis in nonsmall-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 2005; 63:5-24.
69. Prazakova S, Thomas PS, Sandrini A, Yates DH. Asbestos and the lung in the 21st century: an update. Clin Respir J 2014; 8:1-10.